Teclistamab + Daratumumab in Relapsed or Refractory Multiple Myeloma

Generated from prompt:

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

This presentation covers relapsed or refractory multiple myeloma overview, Teclistamab as BCMA x CD3 bispecific antibody, Daratumumab as anti-CD38 monoclonal antibody, their complementary mechanisms, efficacy from MajesTEC-007 trial with ORR 76% and CR 51%, safety profile including manageable CRS, and key takeaways for post-triple-class therapy.

May 5, 202613 slides

Slide 1 of 13

Slide 1 - Teclistamab + Daratumumab

Teclistamab + Daratumumab

in Relapsed or Refractory Multiple Myeloma

---

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Slide 2 of 13

Slide 2 - Presentation Agenda

Multiple Myeloma Overview
Teclistamab
Daratumumab
Combination Rationale
Clinical Trial Results
Safety Profile
Conclusion

---

Photo by Walls.io on Unsplash

Slide 3 of 13

Slide 3 - Multiple Myeloma Overview

Malignancy of plasma cells in bone marrow
Leads to bone lesions, anemia, renal failure, infections
RRMM: Relapsed after ≥2 prior therapies or refractory to last regimen
Median OS in triple-class exposed RRMM: 11-13 months
Unmet need for effective post-triple-class therapies

Slide 4 of 13

Slide 4 - Teclistamab

Teclistamab

BCMA x CD3 Bispecific Antibody

---

Photo by National Cancer Institute on Unsplash

Slide 5 of 13

Slide 5 - Teclistamab: Key Facts

Bispecific antibody: BCMA (tumor) × CD3 (T-cell engager)
Subcutaneous administration: step-up doses then weekly
FDA approved Oct 2022 for RRMM after ≥4 lines incl. immunomodulators, PIs, anti-CD38
Majestec-1 trial: ORR 63% (n=165), CR 39%, median PFS 11.3 months
Manageable CRS (72%, mostly Gr1-2) with step-up dosing

Slide 6 of 13

Slide 6 - Teclistamab Mechanism

Redirects T-cells to BCMA+ myeloma cells
Induces tumor lysis via T-cell activation
Efficacious even at low BCMA levels

---

Photo by National Institute of Allergy and Infectious Diseases on Unsplash

Slide 7 of 13

Slide 7 - Daratumumab

Daratumumab

Anti-CD38 Monoclonal Antibody

---

Photo by insung yoon on Unsplash

Slide 8 of 13

Slide 8 - Daratumumab Efficacy

ORR 31%: Monotherapy (GEN501)
ORR 83%: +Vd (CASTOR)
ORR 93%: +Rd (POLLUX)
SubQ: Approved 2020

Slide 9 of 13

Slide 9 - Combination Therapy

Teclistamab + Daratumumab

Synergistic Targeting in RRMM

---

Photo by camilo jimenez on Unsplash

Slide 10 of 13

Slide 10 - Complementary Mechanisms

Teclistamab

BCMA × CD3 bispecific
T-cell redirection
Deep responses in heavily pretreated

Daratumumab

Anti-CD38 monoclonal
ADCC, complement, phagocytosis
Broad activity, immunomodulation

Slide 11 of 13

Slide 11 - MajesTEC-007: Efficacy (Tecl + Dara)

ORR 76%: Overall Response
CR 51%: Complete Response
89%: ≥VGPR
Ongoing: DOR/PFS

Slide 12 of 13

Slide 12 - Safety and Tolerability

CRS: 74% all Gr (Gr3: 3%), median onset day 4
ICANS: 21% (all Gr1-2)
Infections: 69% (Gr3/4: 36%)
Hematologic AEs: Neutropenia 49% Gr3/4
Discontinuation: 8% due to AEs
Manageable with step-up and prophylaxis

Slide 13 of 13

Slide 13 - Key Takeaways

Teclistamab + Daratumumab delivers high ORR (76%) and CR rates (51%) in heavily pretreated RRMM Complementary mechanisms with manageable toxicity Promising for post-triple-class exposed patients Further data from ongoing trials awaited

Thank you! Questions?

---

Photo by Ian C on Unsplash

Discover More Presentations

Explore thousands of AI-generated presentations for inspiration

Browse Presentations

Create Your Own Presentation

Generate professional presentations in seconds with Karaf's AI. Customize this presentation or start from scratch.

Create New Presentation